Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
HJHiddo J.L. HeerspinkHPHans‐Henrik ParvingDLDennis L. AndressGLGeorge L. BakrisRCRicardo Correa-Rotter
University Medical Center Groningen · University of Groningen · +20 more institutions
Indexed incrossref
Abstract
No abstract available for this paper.
Citation impact
603
total citations
- FWCI
- 53.73
- Percentile
- 100%
- References
- 23
Citations per year
Authors
710- HJHiddo J.L. HeerspinkCorresponding
University Medical Center Groningen, University of Groningen
- HPHans‐Henrik Parving
University of Copenhagen, Aarhus University, Rigshospitalet
- DLDennis L. Andress
AbbVie (United States)
- GLGeorge L. Bakris
University of Chicago, Hypertension Institute
- RCRicardo Correa-Rotter
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Topics & keywords
Topics
Keywords
- Medicine
- Placebo
- Type 2 diabetes
- Kidney disease
- Double blind
- Diabetes mellitus
- Internal medicine
- Sonar
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.